Wuhan Hiteck Biological Pharma (300683.SZ) has obtained a modification of its drug production license, with an expansion of its production scope.

Announcement from Wuhan Hiteck Biological Pharma (300683.SZ): The company recently obtained the "Drug Production License" issued by the Hubei Provincial Drug Administration, which approved the application for changes to the "Drug Production License". The scope of production has been expanded in the changes, while other content remains unchanged. This change in the company's "Drug Production License" involves the information change in the production scope. Under the commission of Hengchang (Guangzhou) New Drug Research Co., Ltd., the company is now permitted to produce Osimertinib Phosphate Granules Suspension. This change is advantageous for the company to leverage its production capacity advantage and better meet market demand.